Gaithersburg, MD, United States of America

Srinath Kasturirangan

This inventor holds 9 USPTO granted patents and 4 published patent applications and 3 EPO patents. Top assignees: Medimmune Limited, Astrazeneca Ab, Other. Active years: 2018-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Srinath Kasturirangan. Retrieved from https://idiyas.com/inventor/srinath-kasturirangan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 4)

% Patents Active = 100.0

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 8.3

ph-index = 2

Forward Citations = 18(Granted Patents)

Company Filing History:

1 out of 834,513

Other

patents

Years Active: 2018-2024

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12065496 - Antibody molecules and conjugates (2024-08-20),

2. RE49908 - Bispecific binding proteins and uses thereof (2024-04-09),

3. 11926657 - Neutralizing anti-influenza binding molecules and uses thereof (2024-03-12),

4. 11524993 - Neutralizing anti-influenza binding molecules and uses thereof (2022-12-13),

5. 11279759 - Bispecific binding proteins and uses thereof (2022-03-22),

6. 10882897 - Neutralizing anti-influenza binding molecules and uses thereof (2021-01-05),

7. 10457732 - Bispecific binding proteins and uses thereof (2019-10-29),

8. 10442854 - Neutralizing anti-influenza binding molecules and uses thereof (2019-10-15),

9. 10160812 - Bispecific HER2 antibodies (2018-12-25),

Title: Innovations and Contributions of Srinath Kasturirangan

Introduction

Srinath Kasturirangan is a notable inventor based in Gaithersburg, MD, with a significant portfolio of nine patents. His work primarily focuses on advancements in antibody molecules and their applications in cancer treatment.

Latest Patents

Among his latest patents, one includes antibody molecules and conjugates that specifically bind to the epidermal growth factor receptor (EGFR) and/or c-Met. These antibody molecules and conjugates are crucial in the treatment of cancer. Another significant patent involves bispecific binding proteins that can bind to two different epitopes. This innovation provides methods for inducing immune responses and offers potential treatments for cancer through the administration of these proteins and their corresponding nucleic acid molecules.

Career Highlights

Srinath has had a distinguished career, working with prominent companies such as MedImmune Limited and AstraZeneca. His contributions in these organizations have been pivotal in advancing biopharmaceutical research and development.

Collaborations

Srinath has collaborated with esteemed colleagues, including Godfrey Rainey and Changshou Gao, enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Srinath Kasturirangan's innovative work in the field of antibody molecules and bispecific proteins showcases his commitment to advancing cancer treatment. His contributions continue to influence the biopharmaceutical industry significantly.

Profile summary based on public USPTO records.